vs
Axos Financial, Inc.（AX）与ICU MEDICAL INC（ICUI）财务数据对比。点击上方公司名可切换其他公司
ICU MEDICAL INC的季度营收约是Axos Financial, Inc.的1.4倍（$540.7M vs $392.2M），Axos Financial, Inc.净利率更高（31.8% vs -2.9%，领先34.7%），过去两年Axos Financial, Inc.的营收复合增速更高（16.1% vs -2.3%）
Axos Financial是总部位于美国内华达州拉斯维加斯的银行控股公司，旗下拥有直销银行Axos Bank，同时提供注册投资顾问服务及电子交易平台，深耕数字化金融赛道，可为用户提供多元便捷的金融服务解决方案。
ICU医疗是总部位于美国加利福尼亚州圣克莱门特的医疗科技企业，专注于研发预防血流感染、保护医护人员免受传染病或危险药物侵害的医疗产品，产品线覆盖静脉治疗用品、输液泵、无针血管通路设备、定制输液套装、危险药物密闭处理系统、传感导管以及无针封闭式血液采样系统等。
AX vs ICUI — 直观对比
营收规模更大
ICUI
是对方的1.4倍
$392.2M
净利率更高
AX
高出34.7%
-2.9%
两年增速更快
AX
近两年复合增速
-2.3%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $392.2M | $540.7M |
| 净利润 | $124.7M | $-15.7M |
| 毛利率 | — | 37.5% |
| 营业利润率 | — | 1.0% |
| 净利率 | 31.8% | -2.9% |
| 营收同比 | — | -14.1% |
| 净利润同比 | 18.5% | 34.0% |
| 每股收益（稀释后） | $2.15 | $-0.63 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AXICUI
| Q1 26 | $392.2M | — | ||
| Q4 25 | $385.1M | $540.7M | ||
| Q3 25 | $323.4M | $537.0M | ||
| Q2 25 | $321.4M | $548.9M | ||
| Q1 25 | $308.8M | $604.7M | ||
| Q4 24 | $307.9M | $629.8M | ||
| Q3 24 | $320.7M | $589.1M | ||
| Q2 24 | $290.9M | $596.5M |
净利润AXICUI
| Q1 26 | $124.7M | — | ||
| Q4 25 | $128.4M | $-15.7M | ||
| Q3 25 | $112.4M | $-3.4M | ||
| Q2 25 | $110.7M | $35.3M | ||
| Q1 25 | $105.2M | $-15.5M | ||
| Q4 24 | $104.7M | $-23.8M | ||
| Q3 24 | $112.3M | $-33.0M | ||
| Q2 24 | $104.9M | $-21.4M |
毛利率AXICUI
| Q1 26 | — | — | ||
| Q4 25 | — | 37.5% | ||
| Q3 25 | — | 37.4% | ||
| Q2 25 | — | 37.9% | ||
| Q1 25 | — | 34.7% | ||
| Q4 24 | — | 36.1% | ||
| Q3 24 | — | 34.8% | ||
| Q2 24 | — | 34.8% |
营业利润率AXICUI
| Q1 26 | — | — | ||
| Q4 25 | 45.6% | 1.0% | ||
| Q3 25 | 46.3% | 2.6% | ||
| Q2 25 | 48.5% | 1.9% | ||
| Q1 25 | 47.9% | 2.1% | ||
| Q4 24 | 48.8% | 6.0% | ||
| Q3 24 | 49.6% | 1.4% | ||
| Q2 24 | 49.6% | 1.3% |
净利率AXICUI
| Q1 26 | 31.8% | — | ||
| Q4 25 | 33.3% | -2.9% | ||
| Q3 25 | 34.7% | -0.6% | ||
| Q2 25 | 34.4% | 6.4% | ||
| Q1 25 | 34.1% | -2.6% | ||
| Q4 24 | 34.0% | -3.8% | ||
| Q3 24 | 35.0% | -5.6% | ||
| Q2 24 | 36.0% | -3.6% |
每股收益（稀释后）AXICUI
| Q1 26 | $2.15 | — | ||
| Q4 25 | $2.22 | $-0.63 | ||
| Q3 25 | $1.94 | $-0.14 | ||
| Q2 25 | $1.89 | $1.43 | ||
| Q1 25 | $1.81 | $-0.63 | ||
| Q4 24 | $1.80 | $-0.97 | ||
| Q3 24 | $1.93 | $-1.35 | ||
| Q2 24 | $1.75 | $-0.88 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $3.1B | $2.1B |
| 总资产 | $29.2B | $4.1B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资AXICUI
| Q1 26 | — | — | ||
| Q4 25 | $1.0B | — | ||
| Q3 25 | $2.6B | — | ||
| Q2 25 | $1.9B | — | ||
| Q1 25 | $2.0B | — | ||
| Q4 24 | $2.4B | $308.6M | ||
| Q3 24 | $2.6B | $312.5M | ||
| Q2 24 | $2.0B | $302.6M |
总债务AXICUI
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $312.7M | — | ||
| Q1 25 | $377.4M | — | ||
| Q4 24 | $358.7M | — | ||
| Q3 24 | $313.5M | — | ||
| Q2 24 | $325.7M | — |
股东权益AXICUI
| Q1 26 | $3.1B | — | ||
| Q4 25 | $2.9B | $2.1B | ||
| Q3 25 | $2.8B | $2.1B | ||
| Q2 25 | $2.7B | $2.1B | ||
| Q1 25 | $2.6B | $2.0B | ||
| Q4 24 | $2.5B | $2.0B | ||
| Q3 24 | $2.4B | $2.0B | ||
| Q2 24 | $2.3B | $2.0B |
总资产AXICUI
| Q1 26 | $29.2B | — | ||
| Q4 25 | $28.2B | $4.1B | ||
| Q3 25 | $27.4B | $4.1B | ||
| Q2 25 | $24.8B | $4.1B | ||
| Q1 25 | $24.0B | $4.2B | ||
| Q4 24 | $23.7B | $4.2B | ||
| Q3 24 | $23.6B | $4.3B | ||
| Q2 24 | $22.9B | $4.3B |
负债/权益比AXICUI
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.12× | — | ||
| Q1 25 | 0.14× | — | ||
| Q4 24 | 0.14× | — | ||
| Q3 24 | 0.13× | — | ||
| Q2 24 | 0.14× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $60.6M |
| 自由现金流经营现金流 - 资本支出 | — | $36.0M |
| 自由现金流率自由现金流/营收 | — | 6.6% |
| 资本支出强度资本支出/营收 | — | 4.6% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $91.8M |
8季度趋势，按日历期对齐
经营现金流AXICUI
| Q1 26 | — | — | ||
| Q4 25 | $104.1M | $60.6M | ||
| Q3 25 | $118.4M | $56.7M | ||
| Q2 25 | $490.3M | $11.2M | ||
| Q1 25 | $73.7M | $51.3M | ||
| Q4 24 | $162.5M | $40.2M | ||
| Q3 24 | $70.8M | $36.1M | ||
| Q2 24 | $305.5M | $82.0M |
自由现金流AXICUI
| Q1 26 | — | — | ||
| Q4 25 | $85.4M | $36.0M | ||
| Q3 25 | $109.3M | $27.6M | ||
| Q2 25 | $436.1M | $-8.5M | ||
| Q1 25 | $65.1M | $36.7M | ||
| Q4 24 | $156.4M | $16.1M | ||
| Q3 24 | $53.0M | $16.2M | ||
| Q2 24 | $269.5M | $62.5M |
自由现金流率AXICUI
| Q1 26 | — | — | ||
| Q4 25 | 22.2% | 6.6% | ||
| Q3 25 | 33.8% | 5.1% | ||
| Q2 25 | 135.7% | -1.5% | ||
| Q1 25 | 21.1% | 6.1% | ||
| Q4 24 | 50.8% | 2.6% | ||
| Q3 24 | 16.5% | 2.7% | ||
| Q2 24 | 92.6% | 10.5% |
资本支出强度AXICUI
| Q1 26 | — | — | ||
| Q4 25 | 4.9% | 4.6% | ||
| Q3 25 | 2.8% | 5.4% | ||
| Q2 25 | 16.9% | 3.6% | ||
| Q1 25 | 2.8% | 2.4% | ||
| Q4 24 | 2.0% | 3.8% | ||
| Q3 24 | 5.5% | 3.4% | ||
| Q2 24 | 12.4% | 3.3% |
现金转化率AXICUI
| Q1 26 | — | — | ||
| Q4 25 | 0.81× | — | ||
| Q3 25 | 1.05× | — | ||
| Q2 25 | 4.43× | 0.32× | ||
| Q1 25 | 0.70× | — | ||
| Q4 24 | 1.55× | — | ||
| Q3 24 | 0.63× | — | ||
| Q2 24 | 2.91× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AX
| Net Interest Income | $306.3M | 78% |
| Noninterest Income | $86.0M | 22% |
ICUI
| Infusion Consumables | $284.7M | 53% |
| Infusion Systems | $176.3M | 33% |
| Vital Care | $79.7M | 15% |
